![]() |
市場調查報告書
商品編碼
1433434
全球塗藥支架市場 2023-2030年Global Drug-Eluting Stent Market 2023-2030 |
預計在預測期(2023-2030年),全球藥物洗脫支架市場將以7.6%的CAGR成長。市場成長的一些主要因素包括老年人口的增加、心血管疾病(週邊和冠狀動脈疾病)盛行率的增加、有利的政府舉措和政策以及新型和增強型技術產品的推出。美國心臟協會(AHA)發表了一篇題為「週邊動脈疾病的健康差異」的文章 AHA 的科學聲明,根據該文章 ,週邊動脈疾病(PAD)影響著全球 2 億人。在美國,某些人口群體的 PAD 盛行率和臨床效果要高得多。 PAD 的社會和臨床影響包括個別殘疾、憂鬱、小截肢和大截肢以及心臟和腦血管事件的發生率較高。
全球藥物洗脫支架市場依材料、產品、類型、應用和最終用戶細分。根據材料,市場細分為不銹鋼、鈷鉻合金等。其他還有鉑鉻合金。根據類型,市場分為永久性和可生物分解。根據應用,市場分為冠狀動脈支架和周邊動脈支架。此外,根據最終用戶,市場細分為醫院和心導管實驗室。在最終用戶中,由於成本較低、效率較高和可用性較高,預計醫院細分市場在預測期內將佔據最大的市場佔有率。
在這些應用中,冠狀動脈支架植入術預計將在預測期內成長。細分市場的成長歸因於冠狀動脈疾病(CAD)發病率的增加、技術進步和有凝聚力的政府政策。在所有CVD中,CAD的盛行率最高。英國心臟基金會(BHF)2023年1月公佈的資料報告指出,2021年最常見的心血管疾病是冠心病(缺血性)心臟病(2019年全球患病率估計為2億)、外周動脈(血管)疾病(1.1億) 、中風(1億)和心房顫動(6000萬)。此外,報告也顯示,北美心臟病和循環系統疾病盛行率為 4,800 萬人,歐洲為 1 億,非洲和中東為 9,800 萬人,拉丁美洲為 4,800 萬人,亞洲和中東地區為 4,800 萬人。澳洲為3.4億。
全球藥物洗脫支架市場根據地理位置進一步細分,包括北美(美國和加拿大)、歐洲(英國、義大利、西班牙、德國、法國和歐洲其他地區)、亞太地區(印度、中國) 、日本、韓國和亞洲其他地區)以及世界其他地區(中東和非洲以及拉丁美洲)。其中,由於老年人口的增加、冠狀動脈疾病的盛行率增加以及醫療保健支出的增加,預計歐洲將在預測期內成長,推動歐洲的藥物洗脫支架市場。
預計在預測期內,北美將在藥物洗脫支架市場中佔據顯著佔有率。隨著老年人口的不斷增加,動脈疾病的發生率也隨之增加,需要更有效的治療解決方案,例如藥物洗脫支架。由於久坐的生活方式和不良的飲食選擇,以動脈斑塊增加為標誌的動脈粥狀硬化盛行率也急劇上升。根據美國國立衛生研究院(NIH)發布的研究報告,2020年3月,美國成年人動脈粥狀硬化性心血管疾病(ASCVD)盛行率為1830萬(8.0%)。這種情況會顯著導致各種心血管疾病,包括心臟病發作和中風。為了應對這種日益嚴重的健康問題,醫療專業人員擴大轉向藥物洗脫支架作為動脈粥狀硬化的首選治療方法。根據美國心臟協會的資料,2020年,在美國,冠狀動脈心臟病(CHD)是美國 CVD 死亡的主要原因(41.2%),其次是中風(17.3%)、其他 CVD(16.8%)、高血壓(12.9%)和心臟衰竭(9.2%)。美國成年人中動脈粥狀硬化性心血管疾病(ASCVD)的盛行率為 1,830 萬人(8.0%)。去年有 690,524 名成年人患有急性冠狀動脈症候群,其中超過 600 萬人處於極高風險。
服務藥物洗脫支架市場的主要公司包括 Abbott Laboratories、Boston Scientific Corp.、Biotronik SE & Co. KG、Medtronic Plc、Terumo Corp. 等。市場參與者透過各種策略(包括併購、夥伴關係、合作、融資和新產品發布),為市場成長做出了巨大貢獻,以保持市場競爭力。例如,2023年 5月,CoSo Health 與 Medinol 簽署了新一代細支柱藥物洗脫支架(DES)EluNIR(TM)在美國的經銷協議。 Medinol 是植入式醫療設備開發的先驅。
Global Drug-eluting Stent Market Size, Share & Trends Analysis Report by material (Stainless Steel, Cobalt-Chromium Alloy, and Others), By Type, (Permanent and Biodegradable), By Application (Coronary Artery Stenting and Peripheral Artery Stenting), and by End-User (Hospitals and Cardiac Catheterization Laboratories), Forecast Period (2024-2031)
The global drug-eluting stent market is anticipated to grow at a CAGR of 7.6% during the forecast period (2023-2030). Some of the major factors attributed to the market growth include the rising geriatric population, increasing prevalence of cardiovascular diseases (peripheral and coronary artery diseases), favorable government initiatives and policies, and the introduction of new and enhanced technological products. The American Heart Association (AHA) published an article called "Health Disparities in Peripheral Artery Disease": A Scientific Statement from the AHA, according to which peripheral artery disease (PAD) affects 200 million individuals globally. In the US, certain demographic groups experience a disproportionately higher prevalence and clinical effect of PAD. The social and clinical effect of PAD includes higher rates of individual disability, depression, minor and major limb amputation along with cardiovascular and cerebrovascular events.
The global drug-eluting stent market is segmented by material, product, type, application, and end-users. Based on the material, the market is sub-segmented into stainless steel, cobalt-chromium alloy, and others. Others include platinum-chromium alloy. Based on the type, the market is sub-segmented into permanent, and biodegradable. Based on the application, the market is divided into coronary artery stenting and peripheral artery stenting. Further, based on end-users, the market is sub-segmented into hospitals and cardiac catheterization laboratories. Among the end-users, the hospitals sub-segment is anticipated to hold the largest market share during the forecast period, owing to the lower costs, higher efficiency, and availability.
Among the applications, the coronary artery stenting sub-segment is expected to grow over the forecast period. Segmental growth is attributed to the increasing incidence of coronary artery diseases (CAD), technological advancements, and cohesive government policies. Among all CVDs, CAD has the highest prevalence. The British Heart Foundation (BHF) data published in January 2023 reported that in 2021, the most common cardiovascular conditions are coronary (ischemic) heart disease (global prevalence estimated at 200 million in 2019), peripheral arterial (vascular) disease (110 million), stroke (100 million) and atrial fibrillation (60 million). Additionally, the report revealed that the prevalence of heart and circulatory diseases in North America was 48 million, in Europe it was 100 million, in Africa and the Middle East it was 98 million, in Latin America it was 48 million, and in Asia and Australia it was 340 million.
The global drug-eluting stent market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to grow over the forecast period, owing to the increasing geriatric population, increasing prevalence of coronary artery diseases the rising healthcare expenditure, driving the drug-eluting stent market in Europe.
North America is expected to hold a prominent share in the Drug-eluting Stent market during the forecast period. With the rising elderly population, there is an increased inclination to arterial diseases, requiring more effective treatment solutions such as drug-eluting stents. The prevalence of atherosclerosis, marked by the increase of plaque in arteries, has also surged owing to sedentary lifestyles and poor dietary choices. According to research reports published by the National Institutes of Health (NIH), in March 2020, the prevalence of atherosclerotic cardiovascular disease (ASCVD) among adults in the US is 18.3 million (8.0%). This condition significantly contributes to various cardiovascular diseases, including heart attacks and strokes. In response to this mounting health concern, medical professionals are increasingly turning to drug-eluting stents as a preferred treatment for atherosclerosis. According to the American Heart Association, in 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), and heart failure (9.2%). The prevalence of atherosclerotic cardiovascular disease (ASCVD) amongst adults in the US is 18.3 million (8.0%). 690,524 adults had an acute coronary syndrome event last year, and over 6 million are at very high risk.
The major companies serving the drug-eluting stent market include Abbott Laboratories, Boston Scientific Corp., Biotronik SE & Co. KG, Medtronic Plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2023, CoSo Health signed a US distribution agreement with Medinol for EluNIR™, a new generation, thin-strut drug-eluting stent (DES). Medinol is a pioneer in the development of implantable medical devices.